Roivant and Priovant Launch Rare Disease Drug Lisraya at $35,000 Monthly Cost

Pharmaceutical companies Roivant Sciences and Priovant Therapeutics introduced the newly approved treatment Lisraya for rare diseases, setting a monthly price point of $35,000 upon its market debut.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

ReutersFrench5d ago

Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month - Reuters

Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month Reuters

Read full article →

Roivant and Priovant Launch Rare Disease Drug Lisraya at $35,000 Monthly Cost

Sources

Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month - Reuters

Related Stories

Broadcom Shares Drop Despite Earnings Beat as Weak Guidance Looms

Major Retailers and Automakers Report Mixed August Sales Figures

Lula’s Lead Over Bolsonaro Narrows in Latest Brazil Poll

Bank of America Raises Microsoft Price Target Amid Shifting Credit Markets